An anti-prostate-specific membrane antigen (PSMA) antibody was fused with the gp3 protein to create an anti-PSMA-M13-SWNT platform that targets prostate cancer cells and can be used for in vivo fluorescence imaging [87]. The gene discussed is FOLH1; the disease is prostate carcinoma.